{"id":915,"date":"2025-05-15T01:41:21","date_gmt":"2025-05-15T08:41:21","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=915"},"modified":"2025-05-15T02:08:43","modified_gmt":"2025-05-15T09:08:43","slug":"cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/","title":{"rendered":"\u62e8\u5eb7\u89c6\u4e91\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u521b\u65b0\u836fCBT-004\u5728\u7f8e\u56fd\u5b8c\u6210\u4e34\u5e8aII\u671f\u5b9e\u9a8c"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u62e8\u5eb7\u89c6\u4e91\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u521b\u65b0\u836fCBT-004\u5728\u7f8e\u56fd\u5b8c\u6210\u4e34\u5e8aII\u671f\u5b9e\u9a8c<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u773c\u79d1\u521b\u65b0\u836f\u4f01\u62e8\u5eb7\u89c6\u4e91 \uff08Cloudbreak Pharma Inc.\uff09\u7ba1\u7ebf\u4e2d\u7528\u4e8e\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\uff08\u53c8\u79f0\u5145\u8840\u6027\u7ed3\u819c\u9ec4\u6591\uff09\u7684CBT-004\u4e8e4\u6708\u5728\u7f8e\u56fd\u5b8c\u6210\u4e34\u5e8aII\u671f\u5b9e\u9a8c\u3002\u521d\u6b65\u7ed3\u679c\u663e\u793a\u773c\u90e8\u5b89\u5168\u6027\u4f18\u5f02\uff0c\u6709\u6548\u6027\u7684\u4e3b\u8981\u7ec8\u70b9\u8fbe\u5230\u8bbe\u8ba1\u8981\u6c42\uff0c\u591a\u9879\u6b21\u8981\u7ec8\u70b9\u4e5f\u8fbe\u5230\u8bbe\u8ba1\u8981\u6c42\u3002<\/span><\/p>

\u62e8\u5eb7\u89c6\u4e91\u662f\u4e00\u5bb6\u521b\u65b0\u9a71\u52a8\u7684\u4e34\u5e8a\u773c\u79d1\u751f\u7269\u6280\u672f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u5f00\u53d1\u521b\u65b0\u6027\u53ca\u5dee\u5f02\u5316\u7597\u6cd5\u3002\u62e8\u5eb7\u89c6\u4e91\u4e8e2015\u5e74\u5728\u7f8e\u56fd\u6210\u7acb\uff0c\u9664\u8bbe\u7acb\u5728\u52a0\u5dde\u5c14\u6e7e\u7684\u603b\u90e8\u5916\uff0c\u5728\u4e2d\u56fd\u5927\u9646\u548c\u4e2d\u56fd\u9999\u6e2f\u4e5f\u6709\u5efa\u7acb\u8fd0\u8425\u673a\u6784\u516c\u53f8\u81f4\u529b\u4e8e\u81ea\u4e3b\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u56fd\u9645\u9996\u521b\u6216\u8005\u540c\u7c7b\u4e2d\u6700\u4f73\u7684\u773c\u79d1\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u62e8\u5eb7\u89c6\u4e91\u5df2\u5efa\u7acb\u4e86\u5e7f\u6cdb\u4e14\u521b\u65b0\u7684\u7ba1\u7ebf\u5305\u62ec\u516b\u79cd\u836f\u7269\u5019\u9009\u7269\uff0c\u6db5\u76d6\u773c\u7403\u524d\u540e\u90e8\u7684\u4e3b\u8981\u75be\u75c5\uff0c\u5176\u4e2d\u56db\u6b3e\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\uff0c\u56db\u6b3e\u5904\u4e8e\u4e34\u5e8a\u524d\u9636\u6bb5\u3002<\/span><\/p>

CBT-004\u662f\u4e00\u79cd\u5c40\u90e8\u6ef4\u773c\u6db2\uff0c\u91c7\u7528\u591a\u6fc0\u9176\u6291\u5236\u5242\uff0c\u9776\u5411\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u53ca\u8840\u5c0f\u677f\u884d\u751f\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff0c\u9002\u7528\u4e8e\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u3002 <\/span>targeting VEGFRs and PDGFRs, is formulated as a topical ocular eyedrop indicated for the treatment of vascularised pinguecula.<\/span><\/p>

\u7751\u88c2\u6591\u662f\u4e00\u79cd\u5706\u5f62\u3001\u6de1\u9ec4\u8272\u7684\u9686\u8d77\u7ec4\u7ec7\uff0c\u957f\u5728\u89d2\u819c\u9644\u8fd1\u7684\u7ed3\u819c\u4e0a\u3002\u4e00\u822c\u800c\u8a00\uff0c\u65e0\u75c7\u72b6\u7684\u7751\u88c2\u6591\u65e0\u9700\u6cbb\u7597\uff0c\u4f46\u5176\u6de1\u9ec4\u8272\u548c\u9686\u8d77\u7684\u8f6e\u5ed3\u53ef\u80fd\u4f1a\u5f15\u8d77\u673a\u68b0\u6027\u6216\u4e0e\u6cea\u819c\u4e0d\u826f\u6709\u5173\u7684\u773c\u8868\u523a\u6fc0\u3002\u7d2b\u5916\u7ebf\u7684\u7d2f\u79ef\u7167\u5c04\u662f\u5bfc\u81f4\u7751\u88c2\u6591\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u5f53\u75c5\u53d8\u90e8\u4f4d\u51fa\u73b0\u8840\u7ba1\u5316\u6216\u53d1\u708e\u65f6\uff0c\u53ef\u80fd\u4f1a\u5bfc\u81f4\u773c\u90e8\u5145\u8840\u3001\u4e0d\u9002\u3001\u75bc\u75db\u3001\u5f02\u7269\u611f\u3001\u6d41\u6cea\u548c\u75d5\u75d2\u7b49\u75c7\u72b6\u3002\u76ee\u524d\u5e76\u65e0\u83b7\u7f8e\u56fd\u836f\u7ba1\u5c40\u6279\u51c6\u9002\u7528\u4e8e\u8840\u7ba1\u5316\u7751\u88c2\u6591\u7684\u836f\u7269\u7597\u6cd5\u3002<\/span><\/p>

CBT-004\u4e8e2023\u5e749\u6708\u9012\u4ea4\u7f8e\u56fd\u836f\u76d1\u5c40\u7533\u8bf7\u5e76\u83b7\u6279\u8fdb\u884c\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u7684\u4e34\u5e8aII\u671f\u7814\u7a76\u3002\u6b64\u9879\u4e34\u5e8a\u5b9e\u9a8c\u5df2\u4e8e2025\u5e744\u6708\u5728\u7f8e\u56fd\u5b8c\u6210\u3002\u521d\u6b65\u6570\u636e\u5206\u6790\u663e\u793aCBT-004\u773c\u90e8\u5b89\u5168\u6027\u4f18\u5f02\u3002\u6b64\u9879\u7814\u7a76\u7684\u4e34\u5e8a\u6709\u6548\u6027\u4e3b\u8981\u7ec8\u70b9\u4e3a\u773c\u90e8\u7ed3\u819c\u7ea2\u80bf\u3002\u6b64\u9879\u6307\u6807\u8fbe\u5230\u4e86\u9884\u671f\u7ed3\u679c\u3002\u4e24\u7ec4CBT-004\u7528\u836f\u7ec4\u4e0e\u5b89\u6170\u5242\u7ec4\u76f8\u6bd4\uff0c\u7ed3\u819c\u7ea2\u80bf\u5206\u6570\u90fd\u6709\u663e\u8457\u4e0b\u964d\uff0c\u5e76\u8fbe\u5230\u7edf\u8ba1\u5b66\u5dee\u5f02\u3002\u4e8e\u6b64\u540c\u65f6\uff0c\u5242\u91cf\u6548\u679c\u7684\u76f8\u5173\u6570\u636e\u663e\u793a\uff0c\u9ad8\u5242\u91cf\u7ec4\u4f18\u4e8e\u4f4e\u5242\u91cf\u7ec4\u3002\u6b64\u5916\uff0c\u591a\u9879\u6709\u6548\u6027\u6b21\u8981\u6307\u6807\uff0c\u7528\u836f\u7ec4\u548c\u5b89\u6170\u5242\u7ec4\u5bf9\u6bd4\u4e5f\u8fbe\u5230\u7edf\u8ba1\u5b66\u5dee\u522b\uff0c\u6709\u663e\u8457\u4e34\u5e8a\u6548\u679c\u3002CBT-004\u4f5c\u4e3a\u4e00\u79cd\u5c0f\u5206\u5b50\u591a\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5728\u975e\u4e34\u5e8a\u836f\u6548\u52a8\u7269\u6a21\u578b\u4ee5\u53ca\u52a8\u7269\u6bd2\u7406\u5b9e\u9a8c\u4e2d\u5747\u663e\u793a\u51fa\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002<\/span><\/p>

\u6839\u636e\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u62a5\u544a\uff0c\u51682023\u5e74\u7684\u8840\u7ba1\u5316\u7751\u88c2\u6591\u60a3\u8005\u4eba\u53e3\u4e3a11.61\u4ebf\u4eba\uff0c\u5176\u4e2d\u7f8e\u56fd\u4e8e2023\u5e74\u7684\u8840\u7ba1\u5316\u7751\u88c2\u6591\u60a3\u8005\u4eba\u53e3\u4e3a4570\u4e07\u4eba\uff0c\u800c\u4e2d\u56fd\u4e8e2023\u5e74\u7684\u8840\u7ba1\u5316\u7751\u88c2\u6591\u60a3\u8005\u4eba\u53e3\u4e3a2070\u4e07\u4eba\u3002\u8840\u7ba1\u5316\u7751\u88c2\u6591\u836f\u7269\u7684\u5168\u7403\u5e02\u573a\u89c4\u6a21\u9884\u671f\u5c06\u4e8e2033\u5e74\u8fbe\u52301.5393\u4ebf\u7f8e\u5143\u3002\u8840\u7ba1\u5316\u7751\u88c2\u6591\u836f\u7269\u7684\u7f8e\u56fd\u53ca\u4e2d\u56fd\u5e02\u573a\u89c4\u6a21\u9884\u671f\u5c06\u4e8e2033\u5e74\u5206\u522b\u8fbe\u52309.406\u4ebf\u7f8e\u5143\u53ca9220\u4e07\u7f8e\u5143\u3002<\/span> The patient population of vascularised pinguecula in China reached 207 million in 2023. The F&S report also mentions that the global market size of vascularised pinguecula drug therapies is expected to reach US$1,539.3 million in 2033. The market size of vascularised pinguecula drug therapies in the United States and China are expected to reach US$940.6 million and US$92.2 million in 2033, respectively.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The […]<\/p>\n","protected":false},"author":16,"featured_media":736,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=915"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/915\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/736"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}